Patents by Inventor Nina RESCHKE

Nina RESCHKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL DARPIN BASED CD123 ENGAGERS
    Publication number: 20240150475
    Abstract: The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for human CD123. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g., acute myeloid leukemia (AML), in mammal, including a human.
    Type: Application
    Filed: March 9, 2022
    Publication date: May 9, 2024
    Inventors: Christian REICHEN, Nina RESCHKE, Bernd SCHLERETH
  • RECOMBINANT CD3 BINDING PROTEINS AND THEIR USE
    Publication number: 20240052033
    Abstract: The present invention relates to recombinant binding proteins comprising a designed ankyrin repeat domain with binding specificity for CD3. In addition, the invention relates to nucleic acids encoding such binding proteins, pharmaceutical compositions comprising such binding proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods of disease-localized activation of T cells, and in methods of treating diseases, such as infectious diseases or cancer, in a mammal, including a human.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 15, 2024
    Inventors: Sebastian GRIMM, Nina RESCHKE, Christian REICHEN, Bernd SCHLERETH, Victor LEVITSKY, Laura JEANBART
  • DARPin based multi-specific t-cell engagers
    Patent number: 11834504
    Abstract: The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: December 5, 2023
    Assignee: MOLECULAR PARTNERS AG
    Inventors: Nina Reschke, Sebastian Grimm, Christian Reichen, Bernd Schlereth, Victor Levitsky, Matteo Bianchi
  • NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERS
    Publication number: 20230056271
    Abstract: The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.
    Type: Application
    Filed: March 9, 2022
    Publication date: February 23, 2023
    Inventors: Nina RESCHKE, Sebastian GRIMM, Christian REICHEN, Bernd SCHLERETH, Victor LEVITSKY, Matteo BIANCHI